Market Overview

UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Raises PT on Mylan

Share:
Related MYL
The Week Ahead: Earnings Season Continues, Several IPOs, Notable Conferences On The Docket
30 Stocks Moving In Monday's Pre-Market Session
Struggling Teva Announces Mass Layoffs (Seeking Alpha)

In a report published Monday, Bank of America Merrill Lynch reiterated its Buy rating on Mylan (NASDAQ: MYL), and slightly raised its price target from $29.00 to $30.00.

BofA Merrill Lynch noted, “With significant acquisitions in '07, MYL transformed itself from a US-only, generic-only story into a global, diversified, vertically-integrated one. Though management's original assumptions for Dey (brands) proved optimistic, we are encouraged by revenue trends in generics and potential for margin improvements. Integration risks and high debt level are key risks, but as the only large, liquid, global generic alternative to Teva, we see MYL as a higher risk, higher reward name.”

Mylan closed on Friday at $27.97.

Latest Ratings for MYL

DateFirmActionFromTo
Oct 2017Morgan StanleyMaintainsEqual-Weight
Oct 2017BTIG ResearchMaintainsBuy
Aug 2017ArgusDowngradesBuyHold

View More Analyst Ratings for MYL
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Price Target Analyst Ratings

 

Related Articles (MYL)

View Comments and Join the Discussion!

Partner Center